Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

Company Overview - Veru is a late-clinical-stage biopharma company that has undergone a comprehensive restructuring effort in 2024 [1] - The company divested its commercial sexual health business for $18 million in 2024, marking a significant pivot in its business strategy [1] Leadership and Experience - Richard Prati, associated with Veru, has nearly 40 years of equity analysis and investment experience, including nearly 20 years on Wall Street [1] - He co-founded American Technology Research and sold the company in 2008, showcasing a strong background in public and private global equity analysis and investing [1]